Future research can optimize this immunotherapeutic strategy for eliciting tumor-specific CD4+ T cell responses by considering antigen dosing and immunogenicity, timing of the therapy, the role of adjuvants, immunosuppressive TME, and combinational strategies (221). Here, CD4 is linked to neoplasm.